ArticleLeukemia research2009

Genetic alteration of a bispecific ligand-directed toxin targeting human CD19 and CD22 receptors resulting in improved efficacy against systemic B cell malignancy.

Daniel A Vallera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.